CymoGen Dx Overview

  • Founded
  • 2010
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

CymoGen Dx General Information


Provider of research products for clinical, research and biopharmaceutical customers. The company engages in the application of fluorescence-based DNA detection technology and provides tools for identifying genomic aberrations in cancer cells found in tissue and bone marrow specimens.

Contact Information

Ownership Status
Financing Status
Formerly Angel backed
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Services
Monitoring Equipment
Primary Office
  • 4 Crotty Lane
  • Suite 100
  • New Windsor, NY 12553
  • United States
+1 (845) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CymoGen Dx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 09-Mar-2015 00000 Completed Generating Revenue
1. Angel (individual) 06-Jul-2010 00000 00000 Completed Startup
To view CymoGen Dx’s complete valuation and funding history, request access »

CymoGen Dx Executive Team (8)

Name Title Board Seat Contact Info
Andrew Rogal President & Chief Executive Officer
Mohammed Harris Director of Technical Service and Research
Richard Cuellar Senior Vice President, IP, Quality Systems and Regulatory Affairs
Marc Siegel Vice President, Business Development
Thomas Moss Chief Medical Officer
You’re viewing 5 of 8 executive team members. Get the full list »